Collegium's Upcoming Investor Conferences: Details Inside
Collegium Pharmaceutical's Engagement in Investor Conferences
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has exciting plans to engage with investors in the coming weeks through their participation in two notable conferences. As the company continues to expand its influence in the biopharmaceutical industry, these events provide an excellent opportunity to showcase its advancements and commitment to improving patient care.
Upcoming Conferences and Presentations
One of the highlights for Collegium is the participation in the Mizuho Neuro & Ophthalmology Summit 2025. The panel presentation for this event is scheduled for Wednesday, May 21, 2025, at 11:25 a.m. ET. This summit represents a key platform for discussing advancements in neuro and ophthalmic therapeutics, aligning with Collegium's focus on comprehensive healthcare solutions.
Following this, Collegium will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. This conference typically attracts a wide array of investors and healthcare stakeholders, making it an ideal venue for Collegium to highlight its innovative products and corporate strategy.
Webcast Availability
The presentation at the Jefferies Global Healthcare Conference will be available for live streaming, allowing interested parties to participate in real-time from the comfort of their locations. For those unable to attend the live event, a replay will be archived on Collegium's website for 90 days post-presentation, ensuring that all stakeholders have access to the crucial information shared during the session.
Collegium's Commitment to Healthcare
Collegium Pharmaceutical is not just about attending conferences; it is actively committed to enhancing the lives of individuals facing serious medical challenges. The company's dedication can be seen in its robust portfolio of responsible pain management medications. A significant part of its growth strategy is centered around the recent acquisition of Jornay PM®, a medication aimed at tackling ADHD, thus marking a strategic expansion into the neuropsychiatric field.
This move represents a key component of Collegium's vision of developing a diversified biopharmaceutical company that prioritizes patient well-being. By integrating products that address chronic pain and related disorders, Collegium is not only broadening its commercial portfolio but also demonstrating a disciplined approach to capital deployment and resource management.
The Future of Collegium
As Collegium pursues its strategic objectives, it aims to strengthen its position within the healthcare landscape. The leadership underlines the importance of innovation and expansion, with Jornay PM leading the growth narrative. This proactive approach is designed to meet evolving patient needs and market demands ahead of the curve.
Contact Information
For those interested in connecting with Collegium Pharmaceutical, the investor relations team is readily available. Ian Karp, Head of Investor Relations, leads this team, with Danielle Jesse acting as the Director of Investor Relations. Stakeholders can reach them through their official email: ir@collegiumpharma.com.
Additionally, media inquiries can be directed to Cheryl Wheeler, the Head of Corporate Communications, at communications@collegiumpharma.com. Collegium values open communication with its investors and the public, ensuring transparency and responsiveness.
Frequently Asked Questions
What is Collegium Pharmaceutical's focus during the conferences?
Collegium aims to engage with investors and share updates on its product portfolio and strategic goals, focusing on pain management and neuropsychiatry.
When are the upcoming conferences Collegium will participate in?
Collegium will participate in the Mizuho Neuro & Ophthalmology Summit on May 21, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025.
Will the presentations be available for streaming?
Yes, the presentation at the Jefferies Global Healthcare Conference will be webcast live and archived on Collegium's website for 90 days.
Who can I contact for more information on Collegium's investor relations?
You can reach out to Ian Karp at ir@collegiumpharma.com for investor-related inquiries.
What is Jornay PM®, and how does it fit into Collegium's strategy?
Jornay PM® is a treatment for ADHD recently acquired by Collegium, which enhances their portfolio and aligns with their strategy to address complex medical conditions.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
